Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly's Necitumumab: FDA Panel To Weigh Modest Survival Benefit Against Thromboembolic Risks

This article was originally published in The Pink Sheet Daily

Executive Summary

Is benefit/risk profile in squamous non-small cell lung cancer impacted by Phase III results from trial in non-squamous population that was halted early due to safety issues?


Related Content

Lilly's Portrazza: Box Warning + Modest Efficacy Could Still = Sales Success
Lilly’s Necitumumab Gains FDA Panel Blessing For Lung Cancer
Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial


Related Companies